There are currently 90 clinical trials open – 56 of which are dedicated solely to the immunotherapy of cancer, lymphoma, and leukemia. These include treatments with specific protein probes that deliver immune cells or special cell-killing substances directly to tumor cells, to RNA vaccines against cancer, or the reactivation of dysfunctional immune cells.